Non-contraceptive health benefits of oral contraceptives

Hugo Júnior Maia, Hugo Maia, Julio Casoy, Júlio Casoy
The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception · 2008 · vol. 13(1) , pp. 17–24 · doi:10.1080/13625180701712745 · PMID:17963179 · W2061345113
review OA: closed CC0 ⤵ 16 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

Combined oral contraceptives reduce gynecological disease risk by inhibiting prostaglandin and estrogen synthesis enzymes like Cox-2 and aromatase, thereby decreasing inflammation in the female genital tract.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The use of combined oral contraceptives (COCs) is associated with a reduced risk of developing endometriosis, myomas, and endometrial and ovarian carcinoma. The mechanisms involved are multiple; next to ovulation suppression, a reduction in inflammation in the genital tract is involved. This is accomplished through inhibition of the endometrial expression of enzymes related to the biosynthesis of prostaglandin and oestrogen, particularly cyclooxygenase type II (Cox-2) and aromatase. The blockade of these enzymatic systems by COCs explains the beneficial effects of these compounds in treating the symptoms, and halting the progression of myomas, endometriosis and adenomyosis, all of which are characterized by increased inflammation. Inhibition of aromatase and Cox-2 expression in the endometrium by COCs may explain their efficacy in controlling the pain and excessive uterine bleeding caused by these pathologies. The reduction of inflammation in the endometrium may also be the mechanism behind the lower incidence of endometrial carcinoma in COC users. The blockade of ovulation and ovarian steroidogenesis, on the other hand, may explain the lesser incidence of ovarian cancer and the improvement of acne in users. In conclusion, inflammation appears to play a pivotal role in the development of various benign and malignant gynecological diseases. COCs reduce inflammation in the female genital tract by blocking enzymes such as Cox-2 and aromatase.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosisadenomyosis

MeSH descriptors

Contraceptives, Oral, Hormonal Contraceptives, Oral, Hormonal Acne Vulgaris Acne Vulgaris Aromatase Aromatase Contraceptives, Oral, Combined Contraceptives, Oral, Combined Cyclooxygenase 2 Cyclooxygenase 2 Endometriosis Endometriosis Female Humans Menorrhagia Menorrhagia Ovarian Neoplasms Ovarian Neoplasms Perimenopause Uterine Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (55)

Cited by (16)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:14:48.452140+00:00
License: CC0 · commercial use OK